Barclays PLC Purchases 151,685 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Barclays PLC raised its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 87.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 324,472 shares of the company's stock after purchasing an additional 151,685 shares during the quarter. Barclays PLC owned 0.22% of Xeris Biopharma worth $925,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Wellington Management Group LLP raised its position in Xeris Biopharma by 11.7% in the 3rd quarter. Wellington Management Group LLP now owns 471,644 shares of the company's stock valued at $1,344,000 after buying an additional 49,535 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of Xeris Biopharma in the 3rd quarter worth $3,197,000. Quantbot Technologies LP purchased a new stake in shares of Xeris Biopharma in the third quarter valued at about $44,000. Intech Investment Management LLC bought a new position in shares of Xeris Biopharma during the third quarter valued at about $130,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Xeris Biopharma during the third quarter worth about $237,000. Institutional investors own 42.75% of the company's stock.

Xeris Biopharma Stock Up 0.3 %

XERS traded up $0.01 during trading on Tuesday, hitting $3.39. 968,013 shares of the company traded hands, compared to its average volume of 1,704,862. Xeris Biopharma Holdings, Inc. has a one year low of $1.69 and a one year high of $3.87. The stock's fifty day moving average is $3.30 and its 200 day moving average is $2.83. The firm has a market cap of $505.38 million, a P/E ratio of -7.53 and a beta of 2.65.

Analyst Ratings Changes

Several research firms have commented on XERS. Piper Sandler lowered shares of Xeris Biopharma from an "overweight" rating to a "neutral" rating and set a $3.00 price objective for the company. in a research note on Monday, November 11th. HC Wainwright increased their price target on Xeris Biopharma from $6.00 to $6.60 and gave the company a "buy" rating in a research report on Monday, November 11th.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.